Chronic erythropoietin treatment limits infarct-size in the myocardium in vitro.

摘要: It has been well established that erythropoietin (EPO) can limit myocardial ischemia/reperfusion injury in a variety of acute settings. However, despite EPO being used chronically to treat anemia the infarct limiting effects long term treatment ( chronic) have never fully investigated. In this study we examined 3 week 5,000 IU/Kg) male Sprague Dawley rats infarction after 35 min ischemia and 2 h reperfusion an vitro isolated heart perfusion model. Treating animals 'once week' failed size significantly compared saline control (54.1% +/- 3.5 v 52.3% 4.4), whereas '3 times regime succeeded reducing (36.2% 3.2 4.4, p < 0.05). To demonstrate effect was not due improved oxygen supply caused by raised hematocrit level, also administered 24 prior ischemia/reperfusion. This again reduced (39.9% 4.4 58.4% 5.0, examine mechanism protection PI3K inhibitor wortmannin nitric oxide synthase L-NAME try abrogate mediated protection. Where block (31.7% 6.0 36.2% 3.2), did (51.6% 5.6 3.2, We chronic limits it does so dependent manner.